Baptist Health Foundation announced that it has received a $5 million grant from the Elaine and Eduardo Saverin Foundation benefiting Baptist Health Miami Neuroscience Institute. The Elaine and Eduardo Saverin Parkinson's Disease Fund will support the Institute’s Parkinson’s disease clinical care program, which will focus on medical care, research, community outreach and technological innovation for patients with Parkinson’s disease. The Foundation will be recognized with the naming of the Elaine and Eduardo Saverin Foundation Auditorium at the planned Kenneth C. Griffin Center at Miami Neuroscience Institute, to be unveiled upon the opening of the Center.
“We’re extremely grateful to Elaine and Eduardo Saverin for this generous grant,” said Alex Villoch, CEO of Baptist Health Foundation. “Their commitment to supporting medical innovation and research perfectly aligns with Miami Neuroscience Institute’s bold vision to drive discoveries and provide extraordinary, compassionate care. Their generosity will help advance the Institute’s Parkinson’s disease research program and support patients affected by this debilitating disease.”
Founded in 2023, the Elaine and Eduardo Saverin Foundation is dedicated to creating lasting impact in healthcare, mental health, education, and wildlife conservation and regenerative futures. The grant benefiting Miami Neuroscience Institute is intended to address urgent needs of Parkinson’s disease patients and increase awareness of the disease while advancing breakthroughs to transform treatment for future generations.
“Eduardo and I chose to support Baptist Health Miami Neuroscience Institute because we recognize an institution truly centered on delivering world-class, holistic care to patients and their families,” said Elaine Saverin, chair of the Foundation. “It brings together compassionate care, rigorous research and thoughtful technological innovation in service of individuals who deserve nothing less. We feel deeply privileged to play a small part in building something that can extend beyond any single patient’s journey, touching lives across communities and giving future generations a genuine reason for hope.”
Michael McDermott, M.D., chief medical executive and Irma & Kalman Bass Endowed Chair in Clinical Neuroscience at Miami Neuroscience Institute, as well as chair of the Department of Neurosciences at Florida International University Herbert Wertheim College of Medicine, remarked, “This grant serves to build on the progress the Institute has made in the field of Parkinson’s disease and other movement disorders. It comes at a pivotal time as we look ahead to the upcoming Kenneth C. Griffin Center, which will allow us to expand our multidisciplinary, patient-centered care and leverage state-of-the-art technology. We are honored by the Saverin Foundation’s trust in us to provide world-class expertise for Parkinson’s patients in our community and beyond.”
Miami Neuroscience Institute provides the most comprehensive and innovative techniques to diagnose and treat the brain, spine and nervous system.” Under the direction of Chief Medical Executive Michael McDermott, M.D., an internationally renowned neurosurgeon, the Institute embraces a multidisciplinary approach to patient care, from nonsurgical treatments and minimally invasive procedures to complex brain and spine surgery. As a national leader in the treatment of movement disorders, Miami Neuroscience Institute ensures that patients receive the most-innovative treatment options to provide the best quality of life possible.
Miami Neuroscience Institute is currently developing the Kenneth C. Griffin Center, a new, state-of-the-art facility that will house the Institute’s growing physician team and offer comprehensive brain and spine care for patients on the campus of Baptist Health Baptist Hospital in Miami. Along with cutting-edge laboratories equipped with the latest technologies, the new building will provide space for Baptist Health to conduct studies in the same facility where patients are treated, strengthening collaboration between researchers and clinicians and advancing the Institute’s research in neuroscience and neurodegenerative disorders.
